<DOC>
	<DOCNO>NCT01451515</DOCNO>
	<brief_summary>This phase II clinical trial use risk-adapted therapy . The treatment acute lymphoblastic leukemia ( ALL ) -based therapy , use multi-agent regimen comprise induction , consolidation , continuation ( maintenance ) phase deliver 24-30 month . Participants classify 3 treatment stratum , base bone marrow/peripheral blood lymphoma cell involvement diagnosis day 8 T-lymphoblastic lymphoma bone marrow/peripheral blood lymphoma cell involvement diagnosis B-lymphoblastic lymphoma . The Primary Objective study : To improve outcome child lymphoblastic lymphoma ( LL ) minimal disseminate disease ( MDD ) equal 1 % diagnosis use MDD- minimal residual disease ( MRD ) - base risk-adapted therapy . The Secondary Objectives study : - To determine event-free overall survival - Investigate relationship Day 8 MRD MDD result EFS</brief_summary>
	<brief_title>NHL16 : Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma</brief_title>
	<detailed_description>TREATMENT PLAN Treatment consist 3 main phase : remission induction , consolidation [ patient central nervous system ( CNS ) disease and/or testicular involvement ] , continuation . - Induction ( 6-7 week ) . - Consolidation participant CNS involvement testicular disease ( 10 week ) . - Reintensification - Participants residual disease time induction therapy may receive 1-2 cycle re-intensification therapy may proceed allogeneic stem cell transplant suitable donor available . - Continuation Therapy ( 98-120 week ) . - Intrathecal Chemotherapy ( day 1 15 ; need also day 8 22 ) TREATMENT SCHEME T lymphoblastic lymphoma : bone marrow/peripheral blood ( BM/PB ) involvement ( MDD/MRD ) : Diagnosis : le 1 % ; Day 8 : +/− ( Stratum 1 ) - Induction - Single dose Cyclophosphamide - Steroid : prednisone - Continuation : 98 week T lymphoblastic lymphoma : BM/PB involvement ( MDD/MRD ) : Diagnosis : equal great 1 % ; Day 8 : − ( Stratum 2 ) - Induction - Fractionated Cyclophosphamide - Steroid : prednisone - Continuation : 98 week T lymphoblastic lymphoma : BM/PB involvement ( MDD/MRD ) : Diagnosis : equal great 1 % ; Day 8 : + ( Stratum 3 ) - Induction - Fractionated Cyclophosphamide - Steroid : prednisone dexamethasone - Continuation : 120 week B lymphoblastic lymphoma : Stage I-III ( Stratum 1 ) - Induction - Single dose Cyclophosphamide - Steroid : prednisone - Continuation : 98 week B lymphoblastic lymphoma : Stage IV testicular ( Stratum 2 ) - Induction - Fractionated Cyclophosphamide - Steroid : prednisone - Continuation : 98 week Patients CNS testicular involvement receive Consolidation therapy prior continuation therapy receive extend maintenance therapy ( 120 week ) . Any patient detectable disease ( MRD , bone marrow biopsy residual mass ) end induction may consider reintensification and/or hematopoietic stem cell transplantation ( HSCT ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<criteria>1 . Diagnosis newly diagnose lymphoblastic lymphoma ( patient must &lt; 25 % tumor cell bone marrow morphology ) 2 . Age ≤ 21 year 3 . Limited prior therapy , include systemic glucocorticoid 1 week less , 1 dose vincristine , emergency radiation therapy mediastinum , 1 dose IT chemotherapy . Other circumstance must clear PI coPI . 4 . Written , inform consent assent follow guideline Institutional Review Board , National Cancer Institute ( NCI ) , Food Drug Administration ( FDA ) , Office Human Research Protections ( OHRP ) . 1 . Participants prior therapy , therapy specify 3 . 2 . Participants pregnant lactating . 3 . Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoblastic lymphoma</keyword>
</DOC>